Harbour BioMed wins $20.2 million patent case against Amgen

Harbour BioMed (HKEX: 02142) won a patent infringement lawsuit against Amgen Inc. and its subsidiary Teneobio Inc., with a Delaware jury awarding the company $20.2 million in damages on June 14.

The jury found that Amgen willfully infringed patents protecting Harbour BioMed's antibody discovery platform technology. The case was originally filed in 2021 by Harbour Antibodies, a member of the Harbour BioMed group.

After three hours of deliberation, the jury returned a unanimous verdict finding Amgen infringed the patent, the infringement was willful, the patent is valid, and Harbour BioMed is entitled to the full $20.2 million in damages requested.

The finding of willful infringement allows Harbour BioMed to petition the judge to triple the award, potentially increasing it to $60.6 million. The company stated this outcome is notable in Delaware, where large jury awards in complex patent cases are uncommon.

The patents in question protect technology invented by Professor Frank Grosveld, a founder of Harbour Antibodies. The trial began on June 8 after several years of litigation.

Harbour BioMed said it will continue enforcing its broader patent portfolio, focusing on another patent with potentially greater financial implications that could represent up to ten times the damages awarded in this case.

The company develops antibody therapeutics in immunology and oncology using its proprietary transgenic rodent technology platform called Harbour Mice. This platform generates fully human monoclonal antibodies in different formats.

You May Also Be Interested In

• Robo.ai names three executives to lead UAE subsidiary Neurovia AI
• AngioDynamics reports fiscal 2026 full-year net sales of $320M
• AIRO's RQ-35 Heidrun drone receives Blue UAS certification